Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Adjunct in partial seizures with or without secondary generalisation; myoclonic seizures (with juvenile myoclonic epilepsy); primary generalised tonic-clonic seizures (with idiopathic generalised epilepsy) Age: Adult |
Dose: Oral – Initially, 500 mg Frequency: twice daily Note: Initially on the 1st day; Adjust dose in increments or decrements of 500 mg twice daily at 2-4 week intervals; Maximum: 1,500 mg twice daily. |
|
Indication: Monotherapy for partial seizures with or without secondary generalisation Age: Adult |
Dose: Oral – Recommended starting dose is 250 mg Frequency: twice daily Note: Increased to an initial therapeutic dose of 500 mg twice daily after 2 weeks; May further increase by 250 mg twice daily every 2 weeks depending upon response; Maximum: 1,500 mg twice daily. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Adjunct in seizures Age: 1 to less than 6 months |
Dose: Oral – Initially, 14 mg/kg Frequency: daily Note: may adjust in increments of 14 mg/kg at 2-week intervals. Maximum: 42 mg/kg daily |
|
Indication: Adjunct in seizures Age: greater than 6 months |
Dose: Oral – Initially, 20 mg/kg Frequency: daily Note: may adjust in increments of 20 mg/kg at 2-week intervals. Maximum: 60 mg/kg daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: End-stage renal disease patients undergoing dialysis |
Dose: Loading dose – 750 mg Note: Followed by 500-1,000 mg once daily; supplemental dose of 250-500 mg after dialysis |
|
Condition: Renal impairment: End-stage renal disease patients undergoing dialysis |
Dose: Maintenance dose – 500-1,000 mg Frequency: once daily Note: supplemental dose of 250-500 mg after dialysis |
Administration
- Can take with/without food
- Regular timing
Side Effect
- Asthenia (11-15%)
- Headache (14-19%)
- Infection (11-15%)
- Increased blood pressure (17% in children Less than 4 years)
- Somnolence (11-15%)
- Drowsiness (2-23%)
- Fatigue (10-11%)
- Anorexia (3-13%)
- Weakness (9-15%)
- Nasopharyngitis (7-15%)
- Cough (2-11%)
- Viral infection (2%)
- Asthma (2%)
- Dizziness (5-9%)
- Nervousness (2-10%)
- Amnesia (2%)
- Anxiety (2-3%)
- Ataxia (3%)
- Depression (2-5%)
- Hostility (10%)
- Paresthesia (2%)
- Sinusitis (2%)
- Diplopia (2%)
- Amblyopia (2%)
- Conjunctivitis (2-3%)
- Albuminuria (4%)
- Abnormal hepatic function tests
- Dyskinesia
- Eczema
- Neutropenia
- Decreased hematocrit
- Leukopenia
- Suicidal tendencies
- Hepatitis
- Pancreatitis
- Bone marrow suppression
- Epidermal necrolysis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Enzyme-inducing antiepiletic drugs
|
No specific effect mentioned
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at a cool temperature (not exceeding 25°C) and dry place, protected from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.